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Abstract
Background: Posterior reversible encephalopathy syndrome (PRES) has been associated with Guillain-Barre
syndrome in rare cases. Here we report a patient in whom PRES was the presenting manifestation of Bickerstaff’s
brainstem encephalitis.
Case presentation: A 75-year-old woman presented with acute onset of hypertension, headache, blurred vision,
and left eyelid drooping. Magnetic resonance imaging of the brain showed characteristic PRES lesions involving the
parietal and occipital lobes bilaterally. On the 6th day after symptom onset, the patient developed complete ptosis
and external ophthalmoplegia of both eyes, progressive ataxia, and bilateral lower limb weakness. Cerebrospinal
fluid analyses revealed albuminocytological dissociation (protein: 66.6 mg/dL, WBC: 0/μl), and nerve conduction
studies showed demyelinating sensorimotor polyneuropathy. The patient developed somnolence and a left
extensor plantar response on the 8th day. A diagnosis of Bickerstaff’s brainstem encephalitis was made. Treatment
with plasmapheresis led to a rapid improvement of clinical symptoms. To date, only five similar cases have been
reported, but this is the only case in which PRES developed prior to treatment.
Conclusions: PRES can be a comorbid condition with Bickerstaff’s brainstem encephalitis, either preceding or
following treatment; caution should be used in patients with either syndrome who exhibit atypical presentations.
Keywords: Bickerstaff’s brainstem encephalitis, Guillain-Barre syndrome, Miller-Fisher syndrome, Posterior reversible
encephalopathy syndrome
Background
Posterior reversible encephalopathy syndrome (PRES) is
characterized by headache, confusion, seizures and visual
loss with different triggers and associated conditions,
such as acute hypertension, acute kidney injury, eclamp-
sia, sepsis, multi-organ failure, and autoimmune disease
[1]. The typical neuroimaging findings are reversible
vasogenic subcortical edema involving the posterior
hemispheres bilaterally. Some case reports have demon-
strated the co-occurrence of Guillain-Barre syndrome
(GBS) (or its spectral disorder) and PRES [2], and intra-
venous immunoglobulin (IVIG) has been implicated as
the cause of PRES in a few cases [3–7]. The incidence
of GBS in the general population is 0.75–2 cases per
100,000 [8]. The actual incidence of PRES is unknown,
but it is estimated to be rare. Therefore, the co-
occurrence of both syndromes is unlikely by chance,
but rather implicates a common pathogenic basis.
Here we report a patient in whom PRES was the
presenting manifestation of Bickerstaff ’s brainstem
encephalitis (BBE) and discuss the possible patho-
physiological mechanisms.
Case presentation
A previously healthy 75-year-old woman complained of
severe headache of the bilateral frontal area, accompan-
ied by blurred vision and mild left eyelid ptosis for
3 days. She had upper respiratory infection symptoms
(cough and sneezing) 2 weeks prior to presentation.
She developed arterial hypertension (210/100 mmHg)
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at the emergency room (on the 4th day after symptom
onset). Neurological examination showed left eyelid
ptosis and limited extraocular movements horizontally
in the left eye with the pupil sparing (Fig. 1). There
were no sympathetic signs, such as miosis and anhydro-
sis, nor any long tract signs. A computed tomography-
angiography (CTA) excluded cerebral aneurysm or
other compressive lesions of the oculomotor nerve.
Brain magnetic resonance imaging (MRI) showed T2-
weighted hyper-intense signal abnormalities in the oc-
cipital lobes bilaterally (Fig. 2), appearing iso-intense on
diffusion-weighted imaging, with an increase of the
apparent diffusion coefficient, consistent with vasogenic
edema. These findings were compatible with the diag-
nosis of PRES. Because of persistent headache and
elevated systolic blood pressure, amlodipine and
olmesartan were administered. However, the conditions
did not improve until nimodipine, 30 mg 4 times a day,
was added. On the next day, partial ptosis of the right
eye developed, followed by bilateral oculomotor and
trochlear nerve palsy. Generalized hyporeflexia with
bilateral flexor plantar responses was noted. The
Romberg test was positive. The finger-nose-finger and
heel-knee-shin tests were bilaterally impaired, and an
ataxic gait was present. On the 6th day, the patient
experienced weakness of the lower limbs bilaterally
(MRC: 3/5) and could no longer stand. The partial
ptosis of the right eyelid progressed to complete ptosis,
and both eyes showed complete external ophthal-
moplegia. A test for acetylcholine receptor antibody
was negative. Additional laboratory studies, including
erythrocyte sedimentation rate, complement factors C3
and C4, antinuclear antibodies, extractable nuclear an-
tigens, antineutrophil cytoplasmic antibody, RNP, anti-
SSA, anti-SSB, anti-dsDNA, rheumatic factor, thyroid
function, estrogen, FSH, LH, cortisol, ACTH, prolactin,
HbA1C, hepatic, and renal function, were within nor-
mal limits. Antibodies against gangliosides (including
GQ1b) were not checked because of unavailability.
Cerebrospinal fluid examination demonstrated albumin-
cytological dissociation (protein: 66.6 mg/dl, white cell
count: 0/μl, glucose: 66 mg/dl (serum glucose: 114 mg/
dl) and albumin: 39.69 mg/dl) and an elevated IgG index
(0.84). A panel of CSF analysis, including cytology,
bacterial culture, fungal culture, and serological titers of
viruses including CMV, HSV1, and HSV2, etc. all
showed negative results. A nerve conduction study
revealed loss of sensory nerve potentials of the bilateral
sural, medial, and ulnar nerves. Motor nerve conduction
studies showed demyelinating and eventually axon sen-
sorimotor polyneuropathy (Table 1), which compatible
with acquired demyelination neuropathy. Needle elec-
tromyography was unrevealing. On the 8th day, the
patient had altered consciousness (Glasgow coma scale
was E3V4M5) and an extensor plantar response on
the left. Hypoxia, uremia, Wernicke’s encephalopathy,
Addison’s disease, hepatic encephalopathy, and alcoholism
Fig. 1 Clinical pictures of our patient on the 5th day. a bilateral
ptosis. b left eye impaired adduction on right gaze
Fig. 2 Brain MRI of our patent on the 4th day. Brain MRI T2-weighted hyper-intense signal abnormalities in the occipital lobes bilaterally
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were excluded on the basis of physical and laboratory
findings; however, euvolemic hyponatremia (Na:119
mEq/L), compatible with syndrome of inappropriate
antidiuretic hormone secretion (SIADH), was noted.
Other co-morbidities for hyponatremia or SIADH in-
cluding malignancy, intracranial infection, hemorrhage,
lung disease…etc., have been excluded in our patient.
A diagnosis of Bickerstaff ’s brainstem encephalitis with
overlapping GBS and SIADH was made. Alternate day
plasmapheresis was instituted for five times and the
hyponatremia was gradually corrected. Her conscious-
ness level and ophthalmoplegia improved gradually,
and she could open her eyes on the 13th day. The
patient received an intensive rehabilitation program
and showed progressive improvement of neurological
deficits. She could walk with cane and showed mild
lower limb weakness (MRC: 4/5) on the 17th day. She
was discharged on the 21st day with residual mild
weakness and dysesthesia of the lower extremities. Two
months later, she had completely recovered.
Conclusions
Our patient presented a clinical and neuroradiological
pattern characteristic of PRES preceding a constellation
of neurological symptoms, including complete ptosis,
external ophthalmoplegia, progressive ataxia, weakness
of the lower limbs bilaterally, altered consciousness,
and a left extensor plantar reflex, which were consistent
with Bickerstaff ’s brainstem encephalitis with overlap-
ping GBS [9]. Although previous reports have suggested
that PRES could be the presenting manifestation of
GBS [10, 11] and could occur in patients with GBS
variants, such as Miller-Fisher syndrome (MFS) or BBE
(Table 2), our case, in contrast to most of the cases,
presented with PRES as the first manifestation of BBE
with overlapping GBS prior to any intervention. Three
previous cases have shown the co-occurrence of MFS
or MFS/ BBE-overlap syndrome and non-hypertensive
PRES; however, in these cases, IVIG treatment was con-
sidered to be the culprit of PRES [4, 5, 12]. One recent
case demonstrated extensive vasogenic edema in BBE
without any intervention; however, whether the vaso-
genic edema of the deep white matter, brainstem, and
cerebellum was attributable to PRES is uncertain [13].
The causal relationship between PRES and BBE is
uncertain, but presumably is similar to that between
PRES and GBS. There are some possible mechanisms
that might explain the association between GBS and
PRES [14]. One of them is dysautonomia. Dysautonomia
is reported in 52 % to two thirds of all GBS patients
[15, 16]. It can lead to a marked blood pressure surge
with overwhelmed cerebrovascular auto-regulation,
causing increased brain-blood capillary permeability,
impaired blood-brain barrier, and eventually the develop-
ment of PRES [17]. The other one is the increased level of
circulating cytokines and chemokines. Pro‐inflammatory
Table 1 Motor nerve conduction study. CMAP: compound
muscle action potential
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Abbreviations: MFS Miller-Fisher syndrome, BEE Bickerstaff brainstem encephalitis, PRES posterior reversible encephalopathy syndrome, OAA ophthalmoplegia,
ataxia, and areflexia, HTN hypertension, URI upper respiratory infection, O occipital lobe, P parietal lobe, T temporal lobe, F frontal lobe
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cytokines, such as interferon‐γ and tumor necrosis
factor‐α, released by T lymphocytes play a critical role
in the pathogenesis of inflammatory demyelination of
the peripheral nervous system [18]. Increased levels of
chemokines, such as CCL2-CCR2, CCL5-CCR5, and
CXCL10-CXCR3, have been found in GBS and experi-
mental autoimmune neuritis in humans and animal
studies, respectively [19, 20]. These pro-inflammatory
mediators may also contribute to the pathogenesis of
PRES by changing capillary permeability and by enhan-
cing the disruption of the blood-brain barrier [21].
The etiology of SIADH in our patient was uncertain,
but we considered it to be comorbidity attributed to her
Bickerstaff ’s brainstem encephalitis. SIADH has been
reported in 7–48 % of patients with GBS [22, 23]. The
mechanism of which was hypothesized to be downward
osmotic resetting and enhanced renal tubular sensitivity
to antidiuretic hormone [24–26]. Of note, SIADH has
been associated with poor outcome in GBS as bulbar
weakness and such as the need of ventilator support or
longer hospitalization period [22]. Fortunately, our pa-
tient did not run into this devastating disease cause.
To conclude, PRES could be the initial presentation of
BBE, either due to an immunological reaction against
both the central and peripheral nervous systems or as a
result of acute hypertension caused by autonomic dys-
function. Although the accurate rate of co-occurrence
of these two syndromes remains to be explored in
large-scale prospective studies, a comorbid PRES
should be considered in patients with initial signs of
GBS or its spectral disorders, especially in those with a
blood pressure surge or visual field defect.
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